Ra Medical Systems to Report Second Quarter 2021 Financial Results on August 16, 2021

Rhea-AI Summary

Ra Medical Systems (NYSE American: RMED) will report its second quarter 2021 financial results on August 16, 2021, after market close. A conference call for the investment community will follow at 1:30 PM PT (4:30 PM ET) to discuss these results and provide a company update. Participants may pre-register for the call to receive a unique PIN for immediate access. The webcast will be archived for 30 days, and a replay will be available for 48 hours. Ra Medical specializes in excimer laser systems for treating vascular and dermatological conditions.

Positive

• Company plans to discuss financial results and updates in a conference call.

Negative

• None.

Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report second quarter 2021 financial results after market close on Monday, August 16, 2021. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update.

Pre-Registration		Participants can pre-register for the conference call here:
		Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
Live Call:		Those who choose not to pre-register can access the live conference by dialing:
		U.S.	866-777-2509
		International	412-317-5413
		Passcode	10157984
Live Webcast:		Ra Medical Website
		The webcast will be archived for 30 days.
Replay:		U.S.	877-344-7529
		Canada	855-669-9658
		International	412-317-0088
		Passcode	10157984
		The replay will be available for 48 hours.

About Ra Medical Systems

Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017 the DABRA excimer laser system received FDA 510(k) clearance in the U.S. for crossing chronic total occlusions, or CTOs, in patients with symptomatic infrainguinal lower extremity vascular disease with an intended use for ablating a channel in occlusive peripheral vascular disease. The Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. DABRA and Pharos are both based on Ra Medical’s core excimer laser technology platform and deploy similar mechanisms of action. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in controlled environments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005062/en/

FAQ

When will Ra Medical Systems report its Q2 2021 financial results?

Ra Medical Systems will report its second quarter 2021 financial results on August 16, 2021, after market close.

What time is the Ra Medical Systems Q2 2021 financial results conference call?

The conference call will be held at 1:30 PM Pacific Time (4:30 PM Eastern Time) on August 16, 2021.

How can I participate in the Ra Medical Systems Q2 2021 conference call?

Participants can pre-register for the conference call or dial in directly using the provided numbers.

Will the Ra Medical Systems conference call be available for replay?

Yes, the replay will be available for 48 hours after the call.

What is the focus of Ra Medical Systems' business?

Ra Medical Systems commercializes excimer lasers and catheters for treating vascular and dermatological diseases.